GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Dr Reddys Laboratories Ltd

Dr Reddy's Laboratories: USFDA inspection of Srikakulam plant closed as VAI

REGULATORY ▲ Positive Development LOW RISK
📅 Filed on BSE: 28 Oct 2026, 06:29 PM IST  ·  BSE ID: 39c9551f-fdf3-4faa-a967-7f36d7182d85
View Original BSE Filing (PDF)
💡
In Simple Terms
The US drug regulator found no major issues at Dr Reddy's Srikakulam plant, closing the inspection without significant concerns.
🤖 AI Summary
  • USFDA inspection at Dr Reddy's Srikakulam plant classified as Voluntary Action Indicated (VAI).
  • This classification officially closes the Pre-Approval and GMP inspection initiated in July 2026.
  • The FTO-SEZ Process Unit-02 at Srikakulam, Andhra Pradesh, was subject to the inspection.
  • Company received intimation regarding the inspection outcome on October 28, 2026.
🏢 How This Affects the Company
📈
Business Impact
The closure of the USFDA inspection with a VAI classification removes a potential regulatory hurdle for products manufactured at the Srikakulam facility, supporting ongoing product approvals and market access.
💰
Financial Impact
While no immediate financial figures are provided, a VAI classification is generally viewed favourably as it averts potential fines or remediation costs associated with critical observations.
⚙️
Operational Impact
This outcome allows the Srikakulam plant to continue its normal operations without immediate mandated changes or intensified oversight from the USFDA.
⚠️
Risk Impact
This announcement mitigates regulatory risk associated with the Srikakulam facility's operations and compliance with US FDA standards.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders regarding this disclosure.
👤
Who Is Affected
All shareholders are informed of a significant regulatory update concerning one of the company's manufacturing facilities.
🔍
Management Signal
The closure of the inspection with a VAI outcome indicates successful management of regulatory compliance at the Srikakulam site.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Any further USFDA communication regarding the Srikakulam plant.
Future plant inspection outcomes from the USFDA.
New product approvals linked to the Srikakulam facility.
LOW RISK Favorable USFDA inspection outcome with VAI classification indicates low immediate regulatory risk.
💡 Investor Takeaway
Dr Reddy's Srikakulam plant inspection by USFDA has been closed with a Voluntary Action Indicated (VAI) classification, confirming no significant issues requiring further action.
📅 Company Track Record
Dr Reddy's Pydibhimavaram plant received USFDA observations in October 2026, and its Srikakulam plant received 3 USFDA observations in July 2026 post-inspection.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was the outcome of the USFDA inspection at Dr Reddy's Srikakulam plant?
The USFDA classified the inspection as Voluntary Action Indicated (VAI) and officially closed it.
Which facility at Dr Reddy's was inspected by the USFDA?
The FTO-SEZ Process Unit-02 at Srikakulam, Andhra Pradesh, was inspected.
When was the USFDA inspection at Dr Reddy's Srikakulam plant conducted?
The Pre-Approval Inspection (PAI) and GMP inspection was conducted prior to the July 29, 2026 intimation.
What does Voluntary Action Indicated (VAI) mean for the USFDA inspection?
VAI means the inspection is closed and the company has indicated its intent to address issues, without the FDA mandating specific actions at this time.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.